Computational Molecular Characterization of the Interaction of Acetylcholine and the NMDA Receptor to Explain the Direct Glycine-Competitive Potentiation of NMDA-Mediated Neuronal Currents

ACS Chem Neurosci. 2022 Jan 19;13(2):229-244. doi: 10.1021/acschemneuro.1c00639. Epub 2022 Jan 6.

Abstract

The activation of N-methyl-d-aspartate receptor (NMDAR) is triggered by the closure of bilobed (D1 and D2) clamshell-like clefts upon binding glycine (Gly) and glutamate. There is evidence that cholinergic compounds modulate NMDAR-mediated currents via direct receptor-ligand interactions; however, molecular bases are unknown. Here, we first propose a mechanistic structure-based explanation for the observed ACh-induced submaximal potentiation of NMDA-elicited currents in striatal neurons by predicting competitive inhibition with Gly. Then, the model was validated, in principle, by confirming that the coapplication of Gly and ACh significantly reduces these neuronal currents. Finally, we delineate the interplay of ACh with the NMDAR by a combination of computational strategies. Crystallographic ACh-bound complexes were studied, revealing a similar ACh binding environment on the GluN1 subunit of the NMDAR. We illustrate how ACh can occupy X-ray monomeric open, dimeric "semiopen" cleft conformations obtained by molecular dynamics and a full-active cryo-EM NMDAR structure, explaining the suboptimal NMDAR electrophysiological activity under the "Venus Flytrap model". At an evolutionary biology level, the binding mode of ACh coincides with that of the homologous ornithine-bound periplasmic LAO binding protein complex. Our computed results indicate an analogous mechanism of action, inasmuch as ACh may stabilize the GluN1 subunit "semiclosed" conformations by inducing direct and indirect D1-to-D2 interdomain bonds. Additionally, an alternative binding site was detected, shared by the known NMDAR allosteric modulators. Experimental and computed results strongly suggest that ACh acts as a Gly-competitive, submaximal potentiating agent of the NMDAR, possibly constituting a novel chemotype for multitarget-directed drug development, e.g., to treat Alzheimer's, and it may lead to a new understanding of glutamatergic neurotransmission.

Keywords: 3D-SAR; Alzheimer’s; DCKA; GluN1; Monte Carlo; N-methyl-d-aspartate NMDA; acetylcholine; bioinformatics; cation−π; chemotype; conformational selection; corpus striatum; cycloleucine; docking; electrostatic complementarity; field points; glycine; induced fit; molecular dynamics; ornithine; patch clamp; trimethylammonium.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Acetylcholine*
  • Glycine / pharmacology
  • N-Methylaspartate
  • Neurons
  • Receptors, N-Methyl-D-Aspartate*

Substances

  • Receptors, N-Methyl-D-Aspartate
  • N-Methylaspartate
  • Acetylcholine
  • Glycine